
浏览全部资源
扫码关注微信
国家儿童医学中心/首都医科大学附属北京儿童医院临床研究中心,北京 100045
副主任药师,硕士。研究方向:儿童临床试验及伦理管理、临床中药学。电话:010-58531216。E-mail:guochunyan205@163.com
收稿:2025-12-11,
修回:2026-04-23,
录用:2026-04-23,
纸质出版:2026-05-15
移动端阅览
郭春彦,张怡,杨禹欣,等.根因分析结合知信行理论的药学服务降低儿童临床试验用药品方案违背发生率的效果评价 [J].中国药房,2026,37(09):1206-1210.
GUO Chunyan,ZHANG Yi,YANG Yuxin,et al.Effect evaluation of pharmaceutical service based on root cause analysis combined with KAP theory on decreasing the protocol violations of investigational medicinal products rate in pediatric clinical trials[J].ZHONGGUO YAOFANG,2026,37(09):1206-1210.
郭春彦,张怡,杨禹欣,等.根因分析结合知信行理论的药学服务降低儿童临床试验用药品方案违背发生率的效果评价 [J].中国药房,2026,37(09):1206-1210. DOI: 10.6039/j.issn.1001-0408.2026.09.17.
GUO Chunyan,ZHANG Yi,YANG Yuxin,et al.Effect evaluation of pharmaceutical service based on root cause analysis combined with KAP theory on decreasing the protocol violations of investigational medicinal products rate in pediatric clinical trials[J].ZHONGGUO YAOFANG,2026,37(09):1206-1210. DOI: 10.6039/j.issn.1001-0408.2026.09.17.
目的
2
探讨基于根因分析(RCA)问题导向与知信行(KAP)理论的药学服务在降低儿童临床试验用药品方案违背发生率方面的应用效果。
方法
2
选取我院2016年1月-2020年12月开展的69个药物临床试验项目的617名研究参与者作为对照组,2022年1月-2025年12月开展的72个药物临床试验项目的868名研究参与者作为观察组。通过对对照组发生的试验用药品方案违背进行RCA,确定方案违背类型及其发生原因。对照组开展药物临床试验常规药学服务;观察组在常规药学服务基础上,基于RCA发现的造成问题的根本原因,从知识、态度、行为3个层面实施精准药学服务。比较两组试验用药品方案违背的发生情况。
结果
2
观察组试验用药品方案违背总体发生率、轻微方案违背发生率、重大方案违背发生率均较对照组显著降低(
P
<0.001)。两组发生的方案违背类型主要为漏用/少用/多用药品、给药时间不符合要求、未按要求调整药品剂量和违背方案合并用药/疫苗等。在试验用药品方案违背的责任主体方面,观察组中由研究参与者及其监护人以及研究人员、偶发性因素为责任主体导致的方案违背发生率均显著低于对照组(
P
<0.001、
P
<0.001、
P
=0.025);而由申办者导致的方案违背发生率与对照组比较差异无统计学意义(
P
>0.05)。
结论
2
由药师主导的基于RCA问题导向结合KAP理论的药学服务,可有效降低儿童临床试验用药品方案违背发生率,从而有效保障研究参与者的安全与权益。
OBJECTIVE
2
To investigate the effect of pharmaceutical services guided by root cause analysis (RCA) in a problem-oriented manner combined with knowledge-attitude-practice (KAP) theory on reducing the incidence of protocol violations of investigational medicinal products in pediatric clinical trials.
METHODS
2
A total of 617 participants from 69 drug clinical trial projects conducted in our hospital from January 2016 to December 2020 were selected as the control group, and 868 participants from 72 drug clinical trial projects from January 2022 to December 2025 as the observation group. RCA was performed on the protocol violations of investigational medicinal product in the control group to identify the types and underlying causes. The control group received routine pharmaceutical services for drug clinical trials, while the observation group was provided with precision pharmaceutical services from the three dimensions of knowledge, attitude and practice on the basis of routine pharmaceutical services, according to the root causes identified by RCA. The occurrence of investigational medicinal products protocol violations was compared between the two groups.
RESULTS
2
The total incidence of protocol violations of investigational medicinal products, as well as the incidences of minor and major protocol violations, were all significantly lower in the observation group than in the control group (
P
<0.001). The main types of protocol violations in both groups included missed/under-/over-dosing of medications, non-adherence to administration time, failure to adjust dosage as required, and combined medication/vaccination in violation of the protocol. Regarding the responsible subjects of protocol violations, the incidences of protocol violations attributed to participants and their guardians as well as investigators and accidental factors were significantly lower in the observation group than in the control group (
P
<0.001,
P
<0.001,
P
=0.025). However, there were no statistically significant differences in the incidences of protocol violations caused by sponsor-related reasons between the two groups (
P
>0.05).
CONCLUSIONS
2
Pharmaceutical services led by pharmacists, based on problem-oriented RCA and combined with KAP theory, can effectively reduce the protocol violations of investigational medicinal products rate in pediatric clinical trials, thereby safeguarding the safety and rights of study participants.
肖爽 , 程金莲 , 朱雪琦 , 等 . 关于临床试验不依从方案问题的探讨 [J ] . 中药新药与临床药理 , 2018 , 29 ( 6 ): 832 - 835 .
李吉 , 漆林艳 , 毛建华 , 等 . 儿科临床试验违背方案分析及应对措施 [J ] . 中国医学伦理学 , 2023 , 36 ( 8 ): 847 - 852 .
郑解元 , 杨嘉永 , 梁嘉莹 . 根因分析法在药库管理中的应用与实践 [J ] . 中国医院药学杂志 , 2023 , 43 ( 24 ): 2829 - 2832 .
刘艳娜 , 魏朝辉 , 田沂凡 . 根因分析法结合PDCA循环在中药调剂工作中的应用效果 [J ] . 医药论坛杂志 , 2023 , 44 ( 21 ): 86 - 89 .
ZAREI F , DEHGHANI A , RATANSIRI A , et al . ChecKAP:a checklist for reporting a knowledge,attitude,and practice (KAP) study [J ] . Asian Pac J Cancer Prev , 2024 , 25 ( 7 ): 2573 - 2577 .
郑爽 , 林晨 , 侯欢 , 等 . 基于知信行模式对含口服糖皮质激素治疗的类风湿关节炎患者的全程管理及效果评价 [J ] . 中国医院药学杂志 , 2022 , 42 ( 12 ): 1249 - 1253 .
卢梦妮 , 张溶津 . 基于知信行干预理论的中成药药学服务模式对患者依从性的改善作用 [J ] . 中医药管理杂志 , 2024 , 32 ( 15 ): 89 - 91 .
吴云 , 段茹 , 丁蓓 , 等 . 药物临床试验中方案违背事件的原因分析与改进措施 [J ] . 药学与临床研究 , 2025 , 33 ( 6 ): 573 - 576 .
黄明志 , 罗俊彪 , 杨俊杰 , 等 . 知信行模式在临床试验中的应用与探索 [J ] . 转化医学杂志 , 2014 , 3 ( 2 ): 96 - 98 .
沙莉莉 , 刘燕 , 魏嘉 , 等 . 根因分析在药物临床试验发生方案违背后的应用 [J ] . 西南国防医药 , 2019 , 29 ( 8 ): 885 - 888 .
洪雪 , 雷雅钦 , 梁力均 , 等 . 临床试验过程中不依从/违背或偏离方案的情况分析与管理探讨 [J ] . 中华医学科研管理杂志 , 2020 , 33 ( 4 ): 315 - 320 .
谢江川 , 谢林利 , 曹丽亚 , 等 . 药物临床试验中常见方案偏离及改进措施 [J ] . 中国药房 , 2022 , 33 ( 13 ): 1554 - 1558 .
单娇娇 , 汤依群 , 史美祺 , 等 . 临床药师干预对抗肿瘤药物临床试验方案偏离的影响 [J ] . 中国临床药理学与治疗学 , 2014 , 19 ( 1 ): 33 - 37 .
刘治利 . 临床试验中方案偏离的伦理问题研究 [D ] . 大连 : 大连医科大学 , 2021 .
BIERER B E , KOPPELMAN E , CROKER A K , et al . Engaging children and adolescents in the design and conduct of paediatric research [J ] . Front Pediatr , 2024 , 12 : 1481754 .
TEODORO D , NADERI N , YAZDANI A , et al . A scoping review of artificial intelligence applications in clinical trial risk assessment [J ] . NPJ Digit Med , 2025 , 8 : 486 .
陈云艳 , 李晓晖 , 文娱 . 药物临床试验815例次方案违背的帕累托图分析 [J ] . 现代医药卫生 , 2024 , 40 ( 10 ): 1700 - 1702 .
梁霄 , 钟慧 , 何巧玲 , 等 . 某机构试验用药品方案违背情况分析及探讨 [J ] . 中国处方药 , 2025 , 23 ( 10 ): 97 - 100 .
0
浏览量
5
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621